Aug 2026
A Dual-Targeting Biomimetic Nanozyme Triggering Hypoxia Relief and Macrophage Reprogramming for Synergistic HCC Immunochemotherapy
MRS treatment effectively reprogrammed the immune response by activating the STING/IRF3 signaling pathway, facilitating the shift of macrophages from a pro-tumor M2-like phenotype to an antitumor M1-like phenotype, resulting in robust tumor growth inhibition with negligible systemic toxicity.
Bi Zhou, Liang Xia, Gengyun Miao et al.
· ACS Applied Nano Materials · 0 citations